![Mahmoud Mahmoudian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mahmoud Mahmoudian
Direktor/Vorstandsmitglied bei BioEclipse Therapeutics, Inc.
Aktive Positionen von Mahmoud Mahmoudian
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BioEclipse Therapeutics, Inc.
![]() BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | 28.01.2022 | - |
Karriereverlauf von Mahmoud Mahmoudian
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
BioEclipse Therapeutics, Inc.
![]() BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Mahmoud Mahmoudian
- Erfahrung